Study S002597

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05997576
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 675
Start: 2023-11-22
Primary completion: 2025-02-17
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:TG103 22.5 mg; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Proportion of participants with weight loss of ≥ 5% at week 40 [From baseline to week 40]
Relative percentage change from baseline in body weight at week 40 [From baseline to week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.